相关临床试验
7
0 进行中
药物批准
0
批准总数
监管机构
0
监管机构数
成立时间
N/A
已完成
6
85.7%
终止
1
14.3%
暂无批准数据
- Commercial healthcare costs are projected to rise 9% in 2027, the highest medical cost trend in nearly two decades, according to PwC's analysis of 27 health plans covering over 103 million members. - Nearly 70% of surveyed health plans ranked providers' use of AI documentation and coding tools as a top-three cost inflator, with about 20% calling AI the number one inflationary trend. - Blue Cross Blue Shield analysis found approximately $663 million in inpatient spending and $1.67 billion in outpatient spending may be tied to AI-powered coding practices. - Experts note that AI follows existing fee-for-service incentives, increasing documentation and coding severity before it can potentially reduce costs through administrative automation.
- CVS Health's Caremark unit will replace Amgen's Prolia and Eli Lilly's Forteo with lower-cost biosimilar and generic alternatives on major commercial formularies starting April 1, 2026. - The formulary changes are expected to reduce prescription costs by more than 50% compared to branded drugs, building on CVS's successful biosimilar strategy that has generated $1.5 billion in gross savings. - This move follows CVS's previous decision to exclude AbbVie's Humira from formularies in favor of biosimilars, with 96% of Caremark members successfully transitioning to cheaper alternatives. - The strategy targets osteoporosis treatments after key patents expired for Prolia in 2025 and Forteo in 2019, opening the market to biosimilar competition.
- Premera Blue Cross Blue Shield becomes the first payer to formally adopt coverage for BrainsWay's accelerated SWIFT Deep TMS protocol for patients ages 15 and older with moderate to severe major depressive disorder. - Optum Behavioral Health expands its medical policy to cover Deep TMS therapy for adolescents aged 15 and older, representing more than 48 million covered lives in one of BrainsWay's most significant single-policy expansions. - The coverage expansions collectively bring BrainsWay's total covered lives to approximately 180 million across multiple major insurers, addressing an estimated 5 million adolescents aged 15-21 affected by major depression in the United States. - BrainsWay shares gained 10.1% following the Optum announcement, with the stock climbing 53.6% over the past six months as payer confidence in non-drug neurostimulation treatments continues to grow.
- UnitedHealthcare updated its policy to cover OMNI Surgical System procedures for mild to moderate open-angle glaucoma treatment, effective October 1, 2025, covering approximately 30 million patients. - A comprehensive meta-analysis of 2,379 eyes demonstrated that OMNI achieves treatment success in approximately 89% of patients with sustained IOP reductions and medication-free outcomes in 66-68% of cases. - The study confirmed OMNI's cost-effectiveness compared to market leader iStent inject, with superior quality-adjusted life years and favorable adverse event profile. - Economic analyses indicate OMNI provides 8.95 QALYs per patient over a lifetime horizon compared to 8.93 for iStent inject, attributed to its better safety profile.
- CVS Health, the largest U.S. pharmacy benefit manager, will not add Gilead's new HIV prevention drug Yeztugo to its commercial plans, citing clinical, financial, and regulatory factors despite the drug's proven 99.9% effectiveness. - The decision reflects concerns over Yeztugo's $28,000 annual list price, with CVS stating it's inappropriate for manufacturers to manipulate guidelines with clinically similar products priced far higher than existing options. - AIDS activists call the decision a "grave disappointment" and missed opportunity, as Yeztugo could be transformative in ending the HIV epidemic that infects 1.3 million people annually. - Gilead remains confident in securing 75% U.S. insurer coverage by year-end and 90% by June 2026, with government programs and several state Medicaid plans already providing coverage.
- The three largest U.S. pharmacy benefit managers have excluded nearly all marketed Humira biosimilars from their 2025 standard formularies, marking a dramatic shift from 2024 when eight products were covered. - PBMs are prioritizing their own private-label biosimilars through subsidiaries like Cordavis, Quallent, and Nuvaila, offering plan sponsors high-list-price and low-list-price options while excluding manufacturer-branded competitors. - Industry experts warn this formulary strategy may discourage future biosimilar market entry and manufacturer investment, potentially reducing long-term competition despite current cost benefits for payers.
- The U.S. Senate has confirmed Dr. Mehmet Oz as the new head of the Centers for Medicare & Medicaid Services (CMS) in a 53-45 vote along party lines. - Dr. Oz, a celebrity physician and former TV host, has pledged to address issues with Medicare Advantage programs and will divest from over 70 companies, including UnitedHealth Group, to avoid conflicts of interest. - The appointment comes amid contentious debates regarding the future of Medicare and Medicaid, with the Trump administration considering significant changes to these healthcare programs.
- The real-world evidence oncology solutions market is projected to grow from $893 million in 2025 to $3.51 billion by 2035, representing a compound annual growth rate of 14.7%. - Market growth is driven by increasing demand for real-world evidence in drug development, rising focus on value-based healthcare, growing global cancer incidence, and advancements in data analytics and AI technologies. - North America is expected to hold the largest market share in 2025, while the Asia-Pacific region is projected to experience the fastest growth during the forecast period. - The datasets segment is expected to account for the largest market share, while pharmaceutical, biotechnology, and medical device companies represent the primary end-user segment.
- Latigo Biotherapeutics has raised $150 million in Series B funding led by Blue Owl Capital to advance its pipeline of non-opioid pain medications targeting NaV1.8 and other pain pathways. - The company's lead candidate LTG-001 is currently in Phase 2 trials for acute pain, with data expected later this year and Phase 3 results anticipated in early 2024. - Latigo aims to develop "best-in-class" alternatives to Vertex Pharmaceuticals' recently approved Journavx, focusing on faster pain relief and broader patient applicability.
• A comprehensive analysis of Medicare Part D claims reveals that CVS, Humana, Cigna, and UnitedHealth Group control 34.1% of all pharmacy spending, with even higher shares in specialty pharmacy segments. • Research demonstrates significant patient steering practices, with specialty drug claims being 19.8 percentage points more likely to be filled at insurer-PBM owned pharmacies than expected without steering. • The study highlights potential market competition concerns, particularly in specialty drug categories where insurer-PBM pharmacy control reaches up to 89.7% for certain therapeutic classes.
